

Levocetirizine dihydrochloride

ALLERZET[®]

5 mg Film-coated Tablet
Antihistamine

FORMULATION

Each film-coated tablet contains:

Levocetirizine dihydrochloride 5 mg

PRODUCT DESCRIPTIONS

Levocetirizine 5 mg (Allerzet[®]) is a white, round, biconvex, film-coated tablet that is plain on both sides.

CLINICAL PHARMACOLOGY

PHARMACODYNAMICS

Levocetirizine, the active enantiomer of cetirizine, is a second generation antihistamine. It selectively antagonizes histamine H₁-receptors. *In vitro* studies have shown that levocetirizine has twice the H₁-receptor affinity of cetirizine.

Levocetirizine (at half of cetirizine dosage) appears to be as potent as cetirizine in inhibiting histamine-induced sneezing, increased nasal airway resistance, and skin wheal and flare. Compared with other antihistamines (e.g., desloratadine, fexofenadine, loratadine), it exhibits greater and more consistent inhibition of histamine-induced wheal and flare.

PHARMACOKINETICS

Levocetirizine is rapidly and extensively absorbed after oral administration. Peak plasma concentrations are seen at 0.5 hour for oral solution and 0.9 hour for tablets following oral administration. Food has no effect on the extent of exposure of levocetirizine, but time to peak plasma concentration is delayed by approximately 1.25 hours and peak plasma concentration is decreased by approximately 36% after administration with a high fat meal. Levocetirizine can, therefore, be administered with or without food.

No tissue distribution data are available in humans, neither concerning the passage of levocetirizine through the blood-brain barrier. Levocetirizine is 90% bound to plasma proteins. The apparent volume of distribution is approximately 0.4 L/kg.

In humans, the extent of levocetirizine metabolism is less than 14% of the dose. Therefore, differences resulting from genetic polymorphism or concomitant intake of enzyme inhibitors are expected to be negligible. Metabolic pathways include aromatic oxidation, N- and O-dealkylation, and taurine conjugation. Due to its low metabolism and absence of metabolic inhibition potential, the interaction of levocetirizine with other substances, or vice-versa, is unlikely.

The plasma elimination half-life of levocetirizine is approximately 8 to 9 hours following oral administration. Mean oral total body clearance is approximately 0.63 mL/kg/min. The major route of excretion of levocetirizine and its metabolites is via urine, accounting for a mean of 85.4% of the dose. Excretion via feces accounts for only 12.9% of the dose. Levocetirizine is excreted both by glomerular filtration and active tubular secretion.

Special Population:

Renal Impairment: The area under the plasma concentration-time curve (AUC) is increased by 1.8-, 3.2-, 4.3-, or 5.7-fold in those with mild, moderate, severe impairment, or end-stage renal disease, respectively. The corresponding increases of half-life estimates were 1.4-, 2.0-, 2.9-, and 4-fold, respectively.

INDICATIONS

This medicine is used for:

- Allergic rhinitis: Symptomatic relief of seasonal (e.g., hay fever) and perennial allergic rhinitis
- Chronic idiopathic urticaria: Symptomatic treatment of uncomplicated skin manifestations

DOSAGE AND ADMINISTRATION

Adults and Children 12 years and older Orally, 1 tablet once a day, at bedtime,
Or, as recommended by a physician.

Use in Elderly

Dose should be carefully selected, usually starting at the lowest dose.

Hepatic and Renal Impairment

No dosage adjustment is necessary for patients with solely hepatic impairment. For renal impairment in adults and children ≥ 12 years old, proper dosage adjustment should be done according to the degree of renal impairment.

Dosage for Symptomatic Treatment of Allergic Rhinitis and Chronic Idiopathic Urticaria in Adults and Children ≥ 12 Years Old with Renal Impairment		
Degree of Renal Impairment	Creatinine Clearance (mL/min)	Oral Levocetirizine Dose
Mild	50 to 79	1 tablet once a day
Moderate	30 to 49	1 tablet once every 2 days
Severe	< 30	1 tablet once every 3 days
End-Stage Renal Disease; Patients Undergoing Dialysis	< 10	CONTRAINDICATED

CONTRAINDICATIONS

- Hypersensitivity to levocetirizine, cetirizine, other piperazine derivatives, or to any component of the product
- Patients with end-stage renal disease (creatinine clearance < 10 mL/min) or undergoing hemodialysis
- Children 6 months to 11 years of age with renal impairment
- Breastfeeding

WARNINGS AND PRECAUTIONS

- Patients with predisposing factors of urinary retention (e.g., spinal cord lesion, prostatic hyperplasia) should use levocetirizine with caution.
 - Concomitant use of levocetirizine with alcohol or other central nervous system (CNS) depressants should be avoided. (See *Interactions with Other Medicaments*)
 - Caution should be observed in epileptic patients and patients at risk of convulsions.
 - Levocetirizine should only be used during pregnancy when clearly needed.
- Somnolence, fatigue and asthenia are associated with levocetirizine treatment. Patients should exercise caution when performing hazardous activities requiring mental alertness and physical coordination (e.g., driving, operating machinery).

INTERACTIONS WITH OTHER MEDICAMENTS

CNS Depressants (e.g., Alcohol): Avoid concomitant use due to possible additive effect (i.e., additional reduction in alertness, additional impairment of CNS performance).

Ritonavir: Ritonavir disposition is not altered but this may cause increased AUC (42%), increased half-life (53%), and decreased clearance (29%) of cetirizine.

Theophylline: Theophylline disposition is not altered but this may cause decreased clearance (16%) of cetirizine.

Ketoconazole: Concomitant administration with cetirizine caused prolongation of QT_c interval (increase of 17.4 msec). However, this interaction was not considered clinically important.

Antipyrine, Azithromycin, Cimetidine, Erythromycin, Ketoconazole, Pseudoephedrine: No clinically important changes in electrocardiogram parameters and no pharmacokinetic interactions were observed with cetirizine.

STATEMENT ON USAGE FOR HIGH RISK GROUPS

Pregnancy: Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. Levocetirizine should only be used during pregnancy when clearly needed.

Lactation: The use of levocetirizine is not recommended in breastfeeding women as it is possibly distributed into milk (cetirizine is distributed into milk).

Elderly: Clinical experience with levocetirizine has not identified differences in responses between the elderly and younger patients. However, dose should be carefully selected for elderly patients, usually starting at the lowest dose due to greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.

Renal Impairment: Levocetirizine is mainly excreted by the kidneys and the risk of adverse effects may be greater in patients with renal impairment. (See *Dosage and Mode of Administration*)

UNDESIRABLE EFFECTS

The most frequently reported adverse effects with levocetirizine include diarrhea, constipation, otitis media, vomiting, cough, pyrexia, epistaxis, asthenia, dry mouth, fatigue, headache, nasopharyngitis, pharyngitis, and somnolence.

- Immune system disorders:** Hypersensitivity (anaphylaxis)
- Metabolic and nutrition disorders:** Edema, increased appetite, weight gain
- Psychiatric disorders:** Aggression, agitation, depression, hallucination, suicidal ideation
- Neurological disorders:** Convulsion, dizziness, dysgeusia, extrapyramidal symptoms, febrile seizure, insomnia, movement disorders (including dystonia and oculogyric crisis), myoclonus, orofacial dyskinesia, paresthesia, seizure, syncope, tic, tremor
- Eye disorders:** Blurred vision, visual disturbances
- Ear and labyrinth disorders:** Vertigo
- Cardiac disorders:** Palpitations, tachycardia
- Vascular disorders:** Severe hypotension
- Respiratory, thoracic and mediastinal disorders:** Dyspnea
- Gastrointestinal disorders:** Nausea
- Hepatobiliary disorders:** Cholestasis, hepatitis
- Skin and subcutaneous tissue disorders:** Acute generalized exanthematous pustulosis (AGEP), angioedema, fixed drug eruption, pruritus, rash, urticaria
- Musculoskeletal and connective tissue disorders:** Arthralgia, urgia, myalgia
- Renal and urinary disorders:** Dysuria, glomerulonephritis, urinary retention
- Pregnancy, puerperium and perinatal conditions:** Stillbirth
- Investigations:** Abnormal liver function tests, blood bilirubin increased, transaminases increased

OVERDOSE AND TREATMENT

Symptoms of levocetirizine overdose in adults may include drowsiness. In children, symptoms are initially agitation and restlessness, followed by drowsiness. No specific antidote is known and overdose is addressed by symptomatic or supportive treatment. Following short-term ingestion, gastric lavage may be considered. Dialysis may be ineffective unless a dialyzable agent was concomitantly ingested.

STORAGE CONDITION

Keep the product out of reach and sight of children.
Store at temperatures not exceeding 30°C.

For suspected adverse drug reaction, seek medical attention immediately and report to the FDA at www.fda.gov.ph AND Unilab at (+632) 858-1000 or productsafety@unilab.com.ph.

By reporting undesirable effects, you can help provide more information on the safety of this medicine.

AVAILABILITY

Levocetirizine dihydrochloride (Allerzet[®]) 5 mg Tablet - Box of 100's (in Alu-Alu blister foil)

CAUTION

Foods, Drugs, Devices, and Cosmetics Act prohibits dispensing without prescription.

Manufactured by AMHERST LABORATORIES, INC.

UNILAB Pharma Philippines, Barangay Mampalasan

Biñan, Laguna, Philippines

for UNILAB, Inc.

No. 666 United Street, Mandaluyong City, Metro Manila, Philippines

DR-XY36974

P300000021559

Reg. IPOPHIL

Date of Revision: 9/2017

Date of First Authorization: 9/2012



Trusted Quality Healthcare